Allscripts Healthcare Solutions (NAS: MDRX) filed its 10-K on Feb. 29. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Allscripts Healthcare Solutions beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share improved.
Margins expanded across the board.
Allscripts Healthcare Solutions reported revenue of $388.2 million. The 19 analysts polled by S&P Capital IQ predicted a top line of $378.4 million on the same basis. GAAP reported sales were 25% higher than the prior-year quarter's $305.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.25. The 21 earnings estimates compiled by S&P Capital IQ anticipated $0.25 per share on the same basis. GAAP EPS were $0.13 for Q4 versus -$0.05 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 44.6%, 20 basis points better than the prior-year quarter. Operating margin was 12.2%, 570 basis points better than the prior-year quarter. Net margin was 6.3%, 980 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $387.3 million. On the bottom line, the average EPS estimate is $0.24.
Next year's average estimate for revenue is $1.63 billion. The average EPS estimate is $1.09.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 455 members out of 479 rating the stock outperform, and 24 members rating it underperform. Among 131 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 128 give Allscripts Healthcare Solutions a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Allscripts Healthcare Solutions is outperform, with an average price target of $24.41.
The health-care investing landscape is littered with also-rans and a few major winners. Is Allscripts Healthcare Solutions performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
Add Allscripts Healthcare Solutions to My Watchlist.